Good afternoon. Thank you for joining us today for CVRx's First Quarter 2022 Earnings Conference Call. Joining me on today's call are the company's President and Chief Executive Officer, Nadim Yared, and its Chief Financial Officer, Jared Oasheim. The remarks today will contain forward-looking statements, including statements about financial guidance. The statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings, including the upcoming Form 10-Q that will be filed with the SEC. I would now like to turn the call over to CVRx's President and Chief Executive Officer, Nadim Yared. Thank you, Mike, and thank everyone for joining us. I'll begin today's call by providing an overview of our first quarter performance, followed by an operational update, a review of our financial results by our CFO, Jared Oasheim, and then I will conclude with our thoughts for the rest of 2022 before turning to Q&As. Starting with the review of the first quarter, our total revenue was $4.1 million, slightly exceeding the top of the range of our guidance for Q1. These results were driven by continued strong growth within our U.S. heart failure business, which generated $2.9 million, an increase of approximately 133% over the first quarter of 2021. I'm very proud of the resilience our business displayed during the first quarter, which was heavily impacted by COVID spikes in both the U.S. and Europe. We experienced significant headwinds in January, followed by an improvement in February and ending with a very strong March. Despite the challenges faced early in the quarter, we were able to grow our U.S. heart failure business revenue, expand our U.S. active implanting centers by 22%, and deliver the highest number of revenue units in a quarter. Turning to an update on the operational progress we made during the first quarter aimed at driving the increased adoption and utilization of Barostim. As a reminder, our focus areas are one, the continued expansion of our commercial infrastructure, two, innovation of our product portfolio, and three, the expansion of the clinical body of evidence. First, let's focus on the continued expansion of our commercial infrastructure, specifically our U.S. direct sales. During the quarter, we added three new territories, bringing the total to 17. We continue to be very impressed with the quality of the sales organization that we are assembling. Our employees remain motivated by the buzz generated by our therapy and its visible impact on our patients. On our last earnings call, we announced two newly launched programs to support physician and patient education. First, a direct-to-consumer marketing pilot program in conjunction with a new branding campaign. We continue to see great early traction with the direct-to-consumer pilot within the select geographic locations where it is running. Additionally, we have started a pilot to expand the patient education component to a few select institutions to alleviate the workload of healthcare providers. If successful, we plan on rolling out this educational program to a greater number of institutions across the country. Another area of focus is the innovation of our product portfolio. Earlier this year, we highlighted three recent PMA supplement submissions made to the FDA related to our Barostim platform. We received approval for the new implantable pulse generator during the first quarter, and subsequent to the end of the quarter, we received approval for the new programmer, which is a tablet form factor with an even simpler programming software. With the approval of both the new IPG and the new programmer, we are now planning an initial commercial launch of the new platform in 2022. We are incredibly proud about what we have been able to accomplish in the first quarter despite the significant headwinds we continue to experience from COVID. The performance seen in February, and particularly in March, is very encouraging as it validates the growing demand for Barostim even during a challenging macro environment. We remain on track to deliver continued growth in the balance of 2022 and help bring relief to patients suffering from cardiovascular diseases. I'll now turn the call over to Jared to review our financials. Jared? Thanks, Nadim. Total revenue generated in the first quarter was $4.1 million, which is an increase of $1.2 million or 43% when compared to the same period last year. Revenue generated in the U.S. was $3.1 million in the current quarter, which is an increase of 90% over the same period last year. Heart failure revenue in the U.S. totaled $2.9 million in the current quarter on a total of 99 revenue units as compared to $1.3 million in the first quarter of last year on 44 revenue units. The increase was primarily driven by the continued growth in the U.S. heart failure business as a result of the expansion into new sales territories, new accounts, and increased physician and patient awareness of Barostim. At the end of the current quarter, we had a total of 56 active implanting centers as compared to 19 on March 31, 2021 and 46 on December 31, 2021. At the end of the current quarter, we had a total of 17 sales territories in the U.S. Compared to six on March 31, 2021, and 14 on December 31, 2021. Revenue generated in Europe was $1 million in the current quarter, which is a decrease of 18% when compared to the same period last year. Total revenue units in Europe decreased from 52 in Q1 of 2021 to 50 in the current quarter. The decrease is due to reduced procedure volumes due to COVID-related headwinds in the month of January. At the end of the current quarter, we had a total of six sales territories in Europe. Gross profit was $3.1 million for the three months ended March 31, 2022, an increase of $1.1 million over the three months ended March 31, 2021. Gross margin increased to 77% for the current quarter compared to 70% for the same period last year. Gross margin for the current quarter was higher due to a decrease in the cost per unit and an increase in the average selling price. This was partially offset by a larger percentage of our revenue units coming from full systems versus battery replacements. New patients receive a full system that includes an IPG and a stimulation lead and have a lower gross margin than a standalone IPG used for a battery replacement. Research and development expenses were $2.3 million for the current quarter, which is an increase of 29% when compared to the same period last year. This change was primarily driven by an increase in compensation expenses due to increased headcount, an increase in clinical study expenses, and an increase in non-cash stock-based compensation expense. SG&A expenses were $10.8 million for the current quarter, which is an increase of 142% when compared to the same period last year. This was primarily driven by an increase in compensation expenses due to increased headcount, as well as an increase in marketing and advertising expenses related to the commercialization of Barostim. Other expense net was $57,000 in the current quarter compared to $3.8 million for the same period last year. The expense in the first quarter of 2021 was primarily driven by the increase in the fair value of the convertible preferred stock warrant liability from December 31, 2020, to March 31, 2021. All of the warrants were converted to common stock warrants as part of the IPO in July 2021. Net loss was $10 million or $0.49 per share for the current quarter as compared to a net loss of $8.6 million or $23.92 per share for the same period last year. Net loss per share was based on 20,453,341 weighted average shares outstanding for the current quarter and 360,675 weighted average shares outstanding for the first quarter of 2021. At the end of the current quarter, cash and cash equivalents were $131.2 million. Net cash used in operating and investing activities was $10.9 million for the current quarter compared to $5.1 million for the same period last year. Now turning to guidance. For the full year of 2022, we continue to expect total revenue between $20 million and $23 million. Gross margin between 74% and 76% and operating expenses between $55 million and $61 million. For the second quarter of 2022, we expect to report total revenue between $4.5 million and $5 million. I would now like to turn the call back over to Nadim. Thanks, Jared. Before opening the line for questions, I would like to discuss our expectations for the balance of 2022 as we seek to drive the increased adoption and utilization of Barostim. First, the continued expansion of our commercial infrastructure, especially our direct sales force in the United States. We expect to continue hiring top talent throughout the year and are targeting a total of approximately 26 U.S. territories by year-end, or on average, adding three new territories per quarter. As we noted previously, we rolled out our new branding campaign that simplified and streamlined our direct-to-consumer messages. The rollout will continue in the remainder of 2022 with the addition of new educational storylines. Our second area of focus is the continued innovation of our product portfolio. With the FDA approval of both the new IPG and programmer, we are planning an initial commercial launch of the new platform in 2022. Our third focus area is the expansion of the clinical body of evidence. The BEAT-HF clinical trial is designed to demonstrate the mortality and morbidity benefit of Barostim in the heart failure with reduced ejection fraction patient population. We remain on track to complete the study on our expected timeline. Looking ahead to the rest of the year, we are excited about the momentum we have built within just the first quarter. We are positioned to leverage that momentum and accelerate the adoption of Barostim. The opportunity remains large, and as always, we remain committed to bringing relief to as many patients as possible that are suffering with cardiovascular illnesses. Now I would like to open the line for questions. Thank you. Ladies and gentlemen, if you'd like to ask a question, please press star then one on your touchtone telephone. Again, if you would like to ask a question, please press star then one. One moment for our first question. Our first question comes from Robbie Marcus of JPMorgan. Your line is open. Great. Congrats on a nice quarter, and thanks for taking the question. Maybe to start, you know, the second quarter guidance, it's in line with where the street is, but I imagine it looks a bit conservative if we take the first quarter exit rate, given the comments that January was the softest and just what we heard from other competitors on, you know, the fact that March was such a large component of sales for first quarter. Love to hear just how you left the quarter and what you've seen so far in April, that gives you that informs the second quarter guidance. Thanks. Yeah. Hey, Robbie, thank you again for listening in and asking the first question. Listen, yes, you are correct. January was weak, driven by the COVID, both the impacts of COVID in the United States and in Germany at the same time. Actually, by the end of January, we were concerned, but we started seeing a little of the light at the end of the tunnel. When we had this conversation in the earnings release in early February, we felt encouraged by the early leading indicator side. Let me remind you of one element. We have a high average selling price device with relatively smaller number of units, i.e., smaller number of patients per center per month. We have some ability of rescheduling within the quarter. What we have seen in the past two quarters is when we had a COVID impact at the beginning of the quarter, we were able to recover by the end. What we have not seen is a push from one quarter to the other. That's why I don't label it as being conservative, maintaining the guidance for next quarter, but rather just playing the average here and not the result of the month of March. I think it's a little bit premature here to take the month of March and extrapolate based on that single month when we know that some of the implants and procedures from January and early February were pushed into March. Does it make sense? Yeah. I mean, if I guess also, I don't know if you're willing, but, you know, what are you seeing so far in April? Yeah. Does that help you form the guide? Yeah, I know. I knew you would ask me this question about April is not over yet, so anything could happen. What we are seeing in April, first, no impact of COVID in the United States nor in Germany, or let me put it this way, very limited impact, if any. Even in Germany this week, there is the German Congress of Cardiology, DGK, that is happening live for the first time in a couple of years. Although the attendance is still low, but finally, a medical meeting in Germany happening live with our team able to meet cardiologists face-to-face and have meaningful conversations, and that was our opportunity to showcase our new brand in Germany. Similarly, in the United States, end of March, we had the American College of Cardiology. Attendance was low, but it was face-to-face. We had really substantive discussions with the cardiologists on site, and we're expecting to continue that trend with HRS, hopefully, but you know, the end of this week, Thursday, Friday, the start of HRS. April seems to be solid and in line with our expectations for a regular month that does not have a COVID impact. That's really helpful. Maybe just last question from me. I would love to see if you have any data points you could give us from the DTC outreach in the limited markets. I know it's still on a small scale and early, but it's a great way to help gauge future patient interest. Just wondering if you have anything there to share. Yeah, absolutely, Robbie. Thank you for asking about my pet project here, the direct-to-consumer education campaign. The way we see this, it is an educational campaign, and the more we can educate patients, the more we simplify the job of the healthcare providers. You know very well, and you probably are hearing this from hospitals and from medical technology companies, medical device companies, that the tight labor is affecting hospital and healthcare providers across the country. Any education that we can provide to the patient directly is a simplification of the process and a reduction of the time constraints on the healthcare provider. So far, we are very happy with the results of our limited campaign, and we are continuing to increase our investment in this space and expand the geography. Of course, we're not talking about states by states or yet a lot of country by country. What we're talking about here is in the United States, we actually advertise on social media about Barostim to ask patients basically to click and learn more about our therapy in ZIP codes around few centers that we have trained to be ready to receive those patients if they were sent to them. That is the process. We called it a pilot early on, and we keep increasing right now the number of ZIP code areas or geographical areas around the sites that have been trained. It's not yet fully deployed in the entire country, far from it, but the early results on a side-by-side basis are extremely encouraging, and we will continue ramping up our investment in this field. Again, thank you for asking this question. Thanks a lot. Thank you. Our next question comes from Matthew O'Brien of Piper Sandler. Your line is open. Great. Thanks for taking the question. Nadim, just to be clear, you know, it sounds like there was some delayed procedures in January, but you were able to make all those up in February and March. None of the March cases got pushed a little bit into April because there's just enough capacity right now at these centers to get these cases done fairly quickly even because there's not as many. Is that fair? That's exactly right, Matthew. Thank you again for asking questions. Okay. The sporadic business I keep talking about, which is a high ASP, smaller volume. Currently, you know, our procedure pays when it's done outpatient very well. So, we don't expect here that it will be deprioritized in an existing site that is already doing procedure. That's why we have not seen procedures pushed from March to April. Okay, got it. As far as the implant centers go, you've tripled the number of active implanting centers in the last year, and you've doubled it in the last nine months. Can you talk about some of the recent additions on the active center side? Are they larger academic centers with a lot of patients or, you know, kind of how has the mix been going between the various centers, and are you starting to open up some things I can count on? Yeah. Yes, excellent question. It's a mix. Let me first, you know, based on our experience in clinical trials in the past, both in hypertension 10 years ago and most recently with BEAT-HF, the academic centers do not necessarily equate to high volume centers. Sometimes some of the community centers in a geography where a community hospital has a broader outreach end up collecting a higher volume of patients that we can see in their databases. Case in point here is what goes on, for example, in Orlando, in heart failure. That's the area where we have the highest number of heart failure hospitalizations in the country. That said, we have a good mix, Matthew, a good mix of academic centers and smaller community centers. The smaller community centers are very practical because the navigation of the process by patients is simplified. It's not as impressive to the patients or daunting to the patients to navigate different departments and different buildings in a big academic institution. That said, we need academic institutions. That's where most of the interesting research is happening. You know, Barostim users can apply for a Barostim investigator-initiated research effort with CVRx to conduct their own post-market research on the therapy. Also, academic institutions are basically the flag holders in many geographies, and the way they go is often the way the smaller community centers do follow. That's why we tend to have a good mix between academic institutions and smaller community centers. Got it. Just last one for me is on access to hospitals. Did you have challenges in January, even part of February, getting access to potentially new centers? Is that something that pressure is kind of lifted at this point? Thanks. Yes, we did. Definitely in Germany, but also in some areas in the United States. I do not recall. I don't think we had any code black in January in the United States, but access was tricky. What was trickier was the fear of patients to go to hospitals when you know all of the talks were about Omicron and the impact or the relative weakness of vaccines to fend off Omicron. If you remember, that was the talk back in December. The staffing shortages at hospitals limited our impact. When a hospital is overloaded with COVID cases and they have to do their usual cases on top of it, they really don't have time to meet with our team, particularly when they are already in a shortage situation themselves. Got it. Very helpful. Thank you. Luckily, we have not seen this much in March, and we're able to deliver a very solid month. For sure. Thanks, Nadim. Thanks, Jared. Oh, thank you, Matthew. Thank you. Have a great day. Thank you. Our next question comes from Brandon Lower of William Blair. Your line is open. For Margaret, thanks for taking the question. First, can we just talk a little bit about, I was curious if you could talk a little bit about the mix of where growth is coming from in terms of new and existing accounts. I know in the past we've talked about how some of these ramping accounts may be nine-12 months out once they start to kinda reach this exit velocity of doing meaningfully more cases. Is that still kinda the case you guys are seeing? And maybe try to give a little bit of color about what kind of growth you're seeing from the new accounts. Yeah, that's Brandon, by the way, very nice seeing you very briefly at ACC. I hope that you had a good meeting there and good discussions. Listen, great question. As we analyze the data, we're always trying to look backward to forecast what's going on to happen forward-looking, right? Looking back here at what we have accomplished so far, we see still a dichotomy between centers who have been activated with us 12 months or more versus those that were activated in the last 12 months, almost a double of the number of revenue units per month. I don't know, Jared, you chime in whenever you want if you're ready to disclose those numbers. But it's very telling, Brandon. The beauty about this is that we know that when a site is starting, they do a couple of patients, they wait to see the impact, they wait for those patients to come for the two-month, six-month visit. Once they see the impact on the patients, they feel more comfortable than doing patient three, four, five, six. The longer the site is doing the procedure, the more they want to do it. That's a great sign about the visible efficacy of the procedure and its impact on the patients and the patients' lives. Jared, I don't know if you wanna chime in here or add more colors. Yeah. I think we talked a little bit last quarter, Brandon, about those centers that have been with us for at least 12 months, starting to approach that long-term goal of having one revenue unit per month. We are continuing to see that trend here where all of those centers that have been with us for more than 12 months are starting to approach that one revenue unit per month. It looks like the long-term goal of hitting one per month is starting to happen right around that 18-month marker for a lot of those longer-term centers. It feels like Nadim has said before in the past, you know, the longer that centers are with us, the more experience they get with patients, the results they are seeing both on the reimbursement side and the efficacy side are just showing them more reasons to go out and treat additional patients. The longer they're with us, the more revenue units and the more patients that are being treated. Got it. That kind of brings up another interesting thought in terms of you guys have obviously a strong balance sheet here. At what point do your kind of or how do you balance maybe using some of this cash to potentially expedite, if possible, that 18-month, 12- to 18-month time frame and ramp accounts more quickly? Or is it something that just needs time or there's no ROI there for you guys? How do you kind of balance the cash spend in that versus the opportunities ahead of you? Brandon, excellent question. Listen, it's a tricky one because think about it this way, if we go too slow, we will never reach cash flow breakeven. If we go too fast, we risk of burning the cash before we achieve to cash flow breakeven. There is a window where we felt when we did all of the analysis early on, when we raised the money from the IPO proceeds, we felt that's where this window is the line that will take us toward cash flow breakeven. Again, there is a degree of uncertainty around this window, but that window is the line that will take us toward cash flow breakeven. We've been very progressive and steady in our investment, the growth of investments. We are adding three territories every quarter, and we plan to continue adding three territories every quarter. Listen, I understand what you're saying, and I like to believe that if we could do it, we would have done it. That means go ahead and hire 20, 50, 100 territories, territory managers all at once and train them. But the fact is, we don't believe that this is the right track forward, and we prefer that steady, slow progress that allow us to put here our foot one step at a time on solid foundations. Does it make sense what I'm trying to express in here? Yep, that's helpful. That makes sense. Thank you. Thank you, Brandon. Send our regards to Margaret, by the way. We will. Thanks. Thank you. Our next question comes from Bill Plovanic of Canaccord. Your line is open. Great. Thanks. Good evening, and thanks for taking my questions. I'm gonna start off with innovation, if I could. Just you mentioned the rollout of the, you know, the new programmer and the new IPG. How should we think about timing for that, pricing for that? Are you going to wait for the MRI indication, label for that? Is that just not necessary given that'll just kinda be an add-on? Bill, hey, how are you? First, excellent question. Listen, the MRI PMA supplement that we submitted to FDA covers not only future products but also past products. Basically, every single Barostim Neo that was implanted in a heart failure subject in the United States will be covered by this MRI conditional compatibility if or when FDA approves it. Therefore, knowing this, it's disconnected from the launch of the new IPG, Implantable Pulse Generator, and the new programmer. Does it make sense why they're disconnected? One is looking forward for the new product. This is the new IPG and the new programmer. The second, the MRI compatibility is not only for the new product, but any patient that received it, even in our trial starting from 2012 in the United States, will now be. Well, if FDA approves the MRI compatibility, patients will be able to undergo an MRI scan in the future. Right. Then how should we think about timing of that? Then, Jared, you know, how do we think about the inventory of the original product, and do you end up taking charges for that or having an impact? Are there startup costs to manufacture the new IPG and programmer, and that's why you're guiding gross margins a little lower? Yeah. Bill, thanks for the question. Just on the first part about when will the release come out. The expectation here is we're building out the inventory for the new programmer, for the new IPG, so we're expecting the launch here in the back half of 2022. As far as the inventory levels for the existing IPG and programmers, we are not expecting significant charges associated with that inventory. It can still be used for other purposes, whether it be for a clinical trial or for other customers. As far as the gross margin piece of it, we did hit 77% gross margin in the first quarter, and the full-year guide is 74%-76%. The real reason for that, staying at 74%-76% just comes down to expectations for the rest of the year. We did exceed expectations on the average selling price in the first quarter. If that comes back down as we add more new centers and continue to see pricing pressure, we could see gross margins come down a little bit. The sales mix. Piece of it. As we sell more and more systems or a higher percentage of our revenue units coming from systems to treat new patients, that will have a negative impact on gross margin, so it could come down slightly there as well. That's the main reason for keeping that guide at 74%-76% for the year. Okay. Would the new IPG and programmer have a higher ASP, or do we just keep the same ASP at this point? Yeah. Yeah, we're keeping the same ASP at this point. Okay. On the last on the innovation topic is just the BATWIRE. I don't think we had any update on that. Just love to get just an update on where we are with the trial and kinda expectations on timing for that. You know, the BATWIRE trial is ongoing, and therefore, we do not have access to the efficacy data. However, we have access to the safety data of the procedure, and so far, it's looking pretty good. I'm very excited with the safety profile that we're seeing of the procedure of implanting the current IPG and the current lead, particularly with the BATWIRE toolkit. However, that said, and you have seen it possibly with other cardiovascular or heart failure trials, enrollments are going very slow this past couple of years as compared to previously. That has surprised us, like it's surprising other companies as well. We keep you know a very open eye here about the enrollment rate, and we know that enrollment in a trial is not a linear progression. It often follows a geometric or exponential progression. If you go back to other trials, you would see that more than 2/3 of the patients are enrolled in the last 1/3 of the time on many, many clinical trials, not only in cardiovascular but outside. That said, when we map all of this, taking this into account, we still believe that we have the time to enroll the trial and get approval in 2024. It's not going per plan right now, the enrollment. It is slower than planned. Okay. Thanks for that. You know, just two things for me. I mean, my understanding, you have a prior auth backlog that you're working off of. Just any commentary on that, how that looks versus prior quarters or what have you. Just any upcoming medical meetings of note we should think of for you. That's it. Thanks for taking my questions. Yeah, no, thank you, Bill. Listen, the medical meeting is next this coming weekend, HRS in San Francisco. We'll be there. We'll have a smaller presence at ISHLT, but our stronger presence with the new brand will be at HRS in San Francisco. In regard to the prior auth, we are not ready to discuss metrics at this stage. However, qualitatively, we're still very excited about the results that we are accomplishing in here. Our prior authorization team is doing a fantastic job. They do a lot of the work behind the scenes, again, to alleviate the workload of healthcare providers, so they don't have to do this work. We try to do it on their behalf. Now, that said, maybe if you are comparing our prior auth program with other companies, for example, Inspire Medical, the difference could be that we have a higher% of patients covered by Medicare, just the age profile of heart failure. About 2/3 of heart failure patients are covered by Medicare. For Medicare patients, we usually do not need a prior auth. For Medicare Advantage, we need a prior auth, and the approval comes very, very fast. We're not building a long pipeline in here for a lot of the patients, only private payer patients who are not covered by Medicare Advantage, where the approval process could take, you know, months rather than days. That volume is relatively smaller to our business. For us, the prior auth program is not a good proxy for how the next quarter is going to shape. Kind of unfortunately, I wish I have more visibility on the next quarter. I'm just like you here when I look at the results of the last month and the current month and try to project forward. Great. Okay. Well, thanks for taking my questions. Thank you, Bill. Thank you. I'm showing no further questions at this time. Let's turn the call back over to the company for any closing remarks. Oh, excellent. Thank you, operator. Thanks everyone for joining us for our first quarter earnings call. We appreciate your ongoing support, and we look forward to updating you on our progress during our next update. Thank you. Thank you. Ladies and gentlemen, this does conclude today's conference. Thank you all for participating. You may now disconnect. Have a great day.